NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex® in Adult Short Bowel Syndrome
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported that four additional patients have successfully achieved independence from parenteral nutrition (PN) and intravenous (IV) fluids while on long-term Gattex® (teduglutide) therapy in STEPS 2, a 24-month open-label study in adult short bowel syndrome (SBS).
To date, seven patients have achieved independence from PN/IV fluids while on Gattex therapy in the ongoing STEPS 2 study. These patients had depended on PN/IV fluids for periods ranging from two to 14 years. SBS is a rare and debilitating condition in which the body is unable to absorb enough nutrients and/or fluids through the gastrointestinal tract and patients chronically depend on PN/IV fluids to survive.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.